Repligen Corporation — FY2012 Form 10-K
Reporting period: Fiscal year ended December 31, 2012. The filing also provides Q4 2012 data. Repligen changed its fiscal year-end in 2011, so FY2012 is 12 months while the principal comparison period, FY2011, is a nine-month transition period; year-over-year growth rates are therefore not like-for-like.
Business context
Repligen develops and sells consumable bioprocessing products, including Protein A, cell-culture growth factors, OPUS chromatography columns, and testing products. The 2011 acquisition of Novozymes Biopharma Sweden expanded the business and manufacturing footprint. In 2012, the company shifted strategic focus toward bioprocessing and reduced investment in therapeutic development.
Key financial results
| Metric | FY2012 | Comparison / context |
|---|---|---|
| Total revenue | $62.3 million | $23.5 million in the prior nine-month period; not a comparable-duration comparison |
| Product revenue | $41.8 million | Reported up 217%; Novozymes contributed $23.4 million, with a longer reporting period and higher key-customer demand also contributing |
| Royalty and other revenue | $20.4 million | Includes $14.8 million in Orencia royalties and $4.9 million recognized from the Pfizer license |
| Gross margin | 40% | 61% in the prior nine-month period and 65% in the nine months ended December 2010; company cited higher costs at the acquired Sweden facility |
| Operating income | $11.1 million | Prior nine-month period had an operating loss of $1.1 million |
| Net income / diluted EPS | $14.2 million / $0.45 | Includes a $2.9 million income tax benefit, principally from a deferred-tax valuation allowance reversal |
| Operating cash flow | $13.4 million | Cash and cash equivalents increased to $29.2 million |
| Cash and marketable securities | $50.0 million | At December 31, 2012, including short- and long-term marketable securities |
| Working capital | $55.5 million | Total assets were $97.0 million; stockholders’ equity was $84.1 million |
| Debt and obligations | $2.1 million long-term obligations | No material borrowing balance is identified in the presented balance sheet; operating leases and purchase commitments total $19.0 million |
Q4 2012: Revenue was $18.8 million, operating income $6.4 million, and net income $9.6 million ($0.30 diluted EPS). Q4 included the $4.9 million Pfizer license revenue and a $3.1 million income tax benefit; these items make reported quarterly earnings less representative of recurring operations.
Material changes and outlook
- Novozymes materially expanded product revenue and operations in Sweden. FY2012 product costs rose to $25.0 million, and gross margin fell to 40% as the acquired facilities incurred higher production costs.
- Management said it had begun cost-reduction efforts at the Sweden and Waltham facilities and expected gross margins to improve in 2013. It also expected operating expenses to decline significantly, primarily from reduced therapeutic-development spending, and SG&A to decrease slightly.
- Management expected 2013 Orencia royalties to increase moderately, but the royalty agreement expires after December 31, 2013. These royalties represented 24% of FY2012 revenue.
- The company stated that current cash was adequate for at least 24 months, absent acquisitions, and expected higher capital expenditures in 2013 and 2014 to expand Waltham. It anticipated continued investment in bioprocessing products.
- On December 28, 2012, Repligen licensed its spinal muscular atrophy program to Pfizer. It recognized $4.9 million of the $5 million upfront payment in FY2012; the payment was received in January 2013. Up to $65 million of future milestones and royalties are contingent on development and commercialization, and Pfizer may terminate for convenience.
- RG1068 received an FDA complete response letter requiring additional clinical efficacy and safety data; Repligen was discussing another Phase III trial and sought a partner. Its European application was withdrawn. RG2833 remained in Phase I, with trial completion expected in the first half of 2013; further significant company-funded development was not anticipated absent a partner or funding.
Risks, contingencies, and unusual items
- Revenue is concentrated: one bioprocessing customer accounted for 42% of FY2012 revenue, while Bristol royalties accounted for 24%. Loss or reduced orders from a major customer could materially affect results.
- The end of Orencia royalties after 2013 creates a revenue transition risk. The filing’s tax-asset assessment also relies on forecasts that include planned cost reductions and predictable revenue.
- Foreign exchange exposure increased with Sweden operations: 28% of FY2012 revenue and 39% of costs and expenses were denominated in foreign currencies, primarily Swedish kronor. The company did not hedge this exposure.
- Other cited risks include acquisition integration and impairment, competition and pricing pressure, manufacturing interruptions or quality failures, regulatory uncertainty for drug candidates, and environmental and safety compliance at manufacturing sites.
- The company reported no known legal proceedings expected to have a material adverse effect. Management and the auditor concluded internal control over financial reporting was effective; the auditor issued unqualified opinions on the financial statements and internal controls.
Important facts for investors to verify
- Whether bioprocessing growth and the planned facility cost reductions deliver the forecast gross-margin improvement.
- How revenue and earnings perform after Orencia royalties end, and whether new bioprocessing revenue or licensing deals offset the loss.
- Actual cash receipts and any milestone progress under the Pfizer agreement, including Pfizer’s continued development plans.
- The sustainability of reported FY2012 and Q4 earnings after isolating the tax benefit, Pfizer license revenue, acquisition-related effects, and unequal comparison periods.
- Customer concentration, Sweden-related foreign-exchange exposure, and the size and timing of planned Waltham capital spending.